SCHEMBL13289170

SCHEMBL13289170

Bc1cnn2c(NCCCNC(=O)c3ccc(OC)cc3)cc(-c3ccccc3Cl)nc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 1/20 0.45
▸ GSK3B P49841 3/20 0.44
▸ CDK2 P24941 3/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ IKBKE Q14164 1/20 0.40
▸ AURKB Q96GD4 1/20 0.40
▸ TBK1 Q9UHD2 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ BRD4 O60885 2/20 0.40
▸ HDAC3 O15379 3/20 0.40
▸ HDAC1 Q13547 1/20 0.40
▸ ABL1 P00519 1/20 0.39
▸ BCR P11274 1/20 0.39
▸ NAMPT P43490 1/20 0.39
▸ CFTR P13569 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13120073 0.90 GSK3B (0.55) KMT2AGSK3BCDK2NPC1RAB9A
SCHEMBL13288811 0.89 CDK2 (0.44) GSK3BCDK2SMN1; SMN2NAMPT
SCHEMBL13289235 0.89 CDK2 (0.45) KMT2AGSK3BCDK2BRD4HDAC3
SCHEMBL13289231 0.87 DRD2 (0.46) GSK3BCDK2HDAC3HDAC1
SCHEMBL13288868 0.87 CDK2 (0.52) GSK3BCDK2CYP1A2CYP2C19BRD4
SCHEMBL13288948 0.85 BRD4 (0.45) KMT2AGSK3BCDK2MAPTBRD4
SCHEMBL13120278 0.85 GSK3B (0.57) KMT2AGSK3BCDK2NPC1RAB9A
SCHEMBL13288952 0.85 CDK2 (0.44) KMT2AGSK3BCDK2MAPTSMN1; SMN2
SCHEMBL14545970 0.84 GSK3B (0.45) GSK3BCDK2CYP1A2CYP2C19HDAC3
SCHEMBL13288754 0.84 CDK2 (0.45) KMT2AGSK3BCDK2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2194058-A1 Pyrazolopyrimidines suitable for the treatment of cancer diseases SCHERING CORPORATION (US) 2010-06-09 — — EP disclosed
Send feedback